THERAPY DOSSIER · th-e36508176724

delta-Ctenitoxin-Pn1a (PnTx4(6-1))

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 27077886 ↗2016Reported benefit

delta-Ctenitoxin-Pn1a, a Peptide from Phoneutria nigriventer Spider Venom, Shows Antinociceptive Effect Involving Opioid and Cannabinoid Systems, in Rats.

RatOtherWistarMaleIntrathecal and intraplantar0.25 to 2 micrograms per site intrathecally; 5 micrograms p…2 h 30 min after carrageenan; 2 h 55 min after prostaglandin E2; 14 days after…

Model: Carrageenan-induced inflammatory pain; sciatic nerve constriction neuropathic pain; prostaglandin E2-induced acute pain

delta-Ctenitoxin-Pn1a produced dose-dependent antinociception in inflammatory, neuropathic and acute pain models, blocked by CB1 and by mu and delta opioid receptor antagonists.

Extraction: extract · Supplied extraction confidence: 0.88. Machine-extracted fields require source verification.

Loading the evidence…